Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

HPTLC-Densitometric Estimation of Anti-hypertensive Drug Combination Azilsartan Medoxomil and Cilnidipine in Combined Dosage Form

HPTLC-Densitometric Estimation of Anti-hypertensive Drug Combination Azilsartan Medoxomil and... Abstract A combination of Azilsartan Medoxomil and Cilnidipine is prescribed in the treatment of Hypertension. The present work represents an accurate and precise high-performance thin layer chromatographic method for the estimation of Azilsartan Medoxomil (AZL) and Cilnidipine (CLN) in combined tablet dosage form. Pre-coated silica gel- G60 F254 aluminum sheet (100 × 100 mm, 0.2 mm layer thickness) were used as stationary phase and Ethyl Acetate: Toluene: Glacial Acetic Acid (5: 4.9: 0.1 %v/v/v) in the mixture was used as mobile phase. The method was linear in the concentration range of 200 - 2000 ng/band for AZL and 50 -500 ng/band for CLN with a correlation coefficient (r2) of 0.996 for AZL and 0.999 for CLN. The proposed method was validated with respect to linearity, accuracy, precision, and robustness as per ICH Q2 (R1) guideline. A forced degradation study was performed to assess the stability indicating the nature of the method. All the degradant peaks were well resolved from the peak of the drug without any interference. The method was successfully applied for the analysis of AZL and CLN in combined tablet formulation. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Analytical Chemistry Letters Taylor & Francis

HPTLC-Densitometric Estimation of Anti-hypertensive Drug Combination Azilsartan Medoxomil and Cilnidipine in Combined Dosage Form

Download PDF
13 pages

Loading next page...
 
/lp/taylor-francis/hptlc-densitometric-estimation-of-anti-hypertensive-drug-combination-9dCvPJ0dYP

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Taylor & Francis
Copyright
© 2023 Har Krishan Bhalla & Sons
ISSN
2230-7532
eISSN
2229-7928
DOI
10.1080/22297928.2023.2195862
Publisher site
See Article on Publisher Site

Abstract

Abstract A combination of Azilsartan Medoxomil and Cilnidipine is prescribed in the treatment of Hypertension. The present work represents an accurate and precise high-performance thin layer chromatographic method for the estimation of Azilsartan Medoxomil (AZL) and Cilnidipine (CLN) in combined tablet dosage form. Pre-coated silica gel- G60 F254 aluminum sheet (100 × 100 mm, 0.2 mm layer thickness) were used as stationary phase and Ethyl Acetate: Toluene: Glacial Acetic Acid (5: 4.9: 0.1 %v/v/v) in the mixture was used as mobile phase. The method was linear in the concentration range of 200 - 2000 ng/band for AZL and 50 -500 ng/band for CLN with a correlation coefficient (r2) of 0.996 for AZL and 0.999 for CLN. The proposed method was validated with respect to linearity, accuracy, precision, and robustness as per ICH Q2 (R1) guideline. A forced degradation study was performed to assess the stability indicating the nature of the method. All the degradant peaks were well resolved from the peak of the drug without any interference. The method was successfully applied for the analysis of AZL and CLN in combined tablet formulation.

Journal

Analytical Chemistry Letters – Taylor & Francis

Published: Jan 2, 2023

Keywords: Azilsartan Medoxomil; Cilnidipine; Validation; High-Performance Thin Layer Chromatography; Anti-hypertensive combination

References

  • Hypertension Therapeu-tics Update: A Brief Clinical Summary on Azilsartan and Cilnidipine
  • Development and validation of stability indicating HPTLC method for estimation of azilsartan medoxomil
  • Development and Validation of Stability Indicating Chromatographic Methods for Determination of Azilsartan Medoxomil in Pharmaceutical Formation
  • Determination of Azilsartan Medoxomil and Chlorthalidone in tablets exposed to forced degradation by using RP-HPLC
  • Development of RP-HPLC method for separation of atorvastatin calcium, amlodipine besylate and azilsartan medoxomil and its application to analyze their tablet dosage forms
  • Analytical and Bio Analytical Method for Quantification of Pure Azilsartan, not its Salts by RP-HPLC
  • Development and Validation of RP-HPLC method for simultaneous estimation of Azilsartan Medoxomil and Chlorthalidone in bulk and tablet dosage form
  • Stability Indicating RP-HPLC Method for Determination of Azilsartan Medoxomil in Pharmaceutical Dosage Form
  • Stability-indicating RP-HPLC method for the simul-taneous estimation of Azilsartan medoxomil and Chlorthalidone in solid dosage forms. Int
  • Stability indicating RP-HPLC method development and validation for estimation of azilsartan medoxomil in tablet dosage form
  • Method Development and Validation for the Determination of Potential Impurities Present in Azilsartan medoxomil Tablets by Reverse Phase Ultra Performance Liquid Chromatography
  • UV spectrophotometric method for the estimation of Azilsartan Medoxomil in bulk and pharmaceutical formulations. World J
  • Rapid LC-MS Compatible Stability Indicating Assay Method for Azilsartan Medoxomil Potassium
  • Simultaneous determination of azilsartan and chlorthalidone in rat and human plasma by liquid chromatography-electrospray tandem mass spectrum
  • Forced degradation, LC–UV, MS and LC–MS–TOF studies on azilsartan: Identification of a known and three new degradation impurities
  • HPTLC Method Development and Validation of Cilnidipine and Metoprolol Succinate in Combined Dosage Form
  • Development and validation of HPTLC method for simultaneous estimation of Olmesartan medoxomil and Cilnidipine in their combined pharmaceutical dosage forms
  • Development and Validation of HPTLC method for simultaneous estimation of Cilnidipine and Valsartan in bulk and tablet dosage form
  • Spectrophotometric Method for the Estimation of Cilnidipine in Bulk and Pharmaceutical Dosage forms
  • Development and Validation of UV spectrophotometric method for the simultaneous estimation of Cilnidipine and Telmisartan in tablet dosage form utilizing simultaneous equation and absorbance ratio method
  • Development and validation of UV spectro-photometric method for simultaneous estimation of cilnidipine and metoprolol succinate in bulk drugs and combined dosage form
  • Development and validation of novel UV and RP-HPLC methods for determination of cilnidipine (a new generation ca channel blocker) in pharmaceutical dosage form
  • RP-HPLC Method for Simultaneous Estimation of Cilnidipine and Chlorthalidone
  • Development and Validation of RP-HPLC method for simultaneous estimation of cilnidipine and Olmesartan medoxomil in their combined tablet dosage form
  • Simultaneous Estimation of Cilnidipine and Valsartan by RP-HPLC in Tablet Formulation
  • RP-HPLC method development and validation for simultaneous estimation of Cilnidipine, Atenolol and Chlorthalidone
  • Development and Validation of Stability Indicating RP-HPLC Method for Estimation of Cilnidipine
  • Stability Indicating Simultaneous Validation of Telmisartan and Cilnidipine with Forced Degradation Behavior Study by RP-HPLC in Tablet Dosage Form
  • Development and Validation of spectrophotometric method for simultaneous estimation of Azilsartan Kamedoxomil and Cilnidipine in synthetic mixture
  • Simultaneous estimation of azilsartan and cilnidipine in bulk by RP-HPLC and assessment of its applicability in marketed tablet dosage form
  • Development and Validation of Fast and Robust Stability Indicating RP-HPLC Method for Simultaneous Estimation of Azilsartan Medoxomil and Cilnidipine in Pharmaceutical Dosage Form
  • Application of Taguchi OA and Box-Behnken Design for the Implementation of DoE-based AQbD Approach to HPTLC Method for Simul-taneous Estimation of Azilsartan and Cilnidi-pine
  • Application of Chemometry and Design of Experiments to Green HPTLC Method for Synchronous Estimation of Multiple FDCs of Cilnidipine